Why Replimune Stock Was Soaring Today

Key Points The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. 10 stocks we like better than Replimune Group › Biotech stocks can be volatile, a tendency that was very much in Replimune Group's (NASDAQ: REPL) favor on Monday. The biotech's stock had more than doubled in late-session action, thanks to some very positive news on the regulatory front. Its rise was easily eclipsing the S&P 500 index, which at that point was ...